Capital International Ltd. CA Has $3.60 Million Holdings in Ascendis Pharma A/S $ASND

Capital International Ltd. CA decreased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 22.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,861 shares of the biotechnology company’s stock after selling 4,811 shares during the quarter. Capital International Ltd. CA’s holdings in Ascendis Pharma A/S were worth $3,595,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Havemeyer Place LP bought a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $288,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $639,000. State of Wyoming bought a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $175,000. Cibc World Market Inc. lifted its holdings in shares of Ascendis Pharma A/S by 3.1% in the fourth quarter. Cibc World Market Inc. now owns 6,361 shares of the biotechnology company’s stock valued at $1,356,000 after purchasing an additional 193 shares in the last quarter. Finally, Main Management ETF Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the biotechnology company’s stock valued at $2,338,000 after purchasing an additional 112 shares in the last quarter.

Analyst Ratings Changes

ASND has been the topic of a number of research reports. Morgan Stanley restated an “overweight” rating and issued a $256.00 price target on shares of Ascendis Pharma A/S in a report on Thursday, February 12th. Citigroup initiated coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They issued a “buy” rating and a $355.00 price target on the stock. Wedbush restated an “outperform” rating and issued a $273.00 price target on shares of Ascendis Pharma A/S in a report on Thursday, April 9th. Royal Bank Of Canada lifted their target price on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Finally, Barclays lifted their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $295.39.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $210.45 on Monday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The stock’s 50-day simple moving average is $233.16 and its 200 day simple moving average is $223.65. The company has a market cap of $13.13 billion, a P/E ratio of 24.27 and a beta of 0.39. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post 12.85 EPS for the current fiscal year.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of the stock in a transaction on Tuesday, May 26th. The shares were purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the transaction, the director directly owned 400 shares in the company, valued at $95,120. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. 40.00% of the stock is currently owned by insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.